Chinese Health Authorities, Alarmed By Prospect Of 100 Million-plus Diabetics, Create Doctor Training Programs As Global Drug Outfits Step Up R&D
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Alarmed by a 2010 study that showed China lies at the epicenter of an explosion in new diabetes cases, China's Ministry of Health is stepping up physician training courses and planning screening services across major cities, according to Chinese and Western scholars
You may also be interested in...
As Lilly Wades Through The Patent Cliff, It Sees Hope In Emerging Markets
Citi Investment Research says Lilly is the “best positioned” among U.S. pharma in China; here’s why.
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year